The European Society of Medical Oncology Conference (ESMO) in Paris has wrapped up and there was much to talk about as Europe’s top oncologists came together to announce their breakthroughs, disappointments and everything inbetween. As always, the Evaluate Vantage team stayed on top of all the announcements to report back on the key highlights and to make sure that our readers didn’t miss any of the big announcements, including bad news from Lumakas in lung cancer and the hotting up of competition in liver cancer. And, of course, they also looked at the likely stock impact implications of what was said (and not said) during the meeting. 

This eBook brings together all the highlights from the meeting. 



Front-line liver cancer showdown
Duelling datasets
Last-minute Kras entry takes centre stage
Sanofi and Roche’s duelling Serd duds
Mirati needs some colorectal cancer urgency
Trodelvy’s improving trajectory might not matter much
The new liver cancer entrants line up
Keytruda secures a renal cancer monopoly
Keytruda secures a renal cancer monopoly